- Home
- TCRX vs XBIT Comparison
TCRX vs XBIT Comparison
Compare TCRX & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRX
- XBIT
- Stock Information
- Founded
- TCRX 2018
- XBIT 2005
- Country
- TCRX United States
- XBIT United States
- Employees
- TCRX N/A
- XBIT N/A
- Industry
- TCRX Biotechnology: Pharmaceutical Preparations
- XBIT Pharmaceuticals and Biotechnology
- Sector
- TCRX Health Care
- XBIT Health Care
- Exchange
- TCRX Nasdaq
- XBIT Nasdaq
- Market Cap
- TCRX 91.7M
- XBIT 86.3M
- IPO Year
- TCRX 2021
- XBIT 2015
- Fundamental
- Price
- TCRX $1.91
- XBIT $2.92
- Analyst Decision
- TCRX Strong Buy
- XBIT
- Analyst Count
- TCRX 5
- XBIT 0
- Target Price
- TCRX $9.40
- XBIT N/A
- AVG Volume (30 Days)
- TCRX 208.8K
- XBIT 48.3K
- Earning Date
- TCRX 08-12-2025
- XBIT 08-13-2025
- Dividend Yield
- TCRX N/A
- XBIT N/A
- EPS Growth
- TCRX N/A
- XBIT N/A
- EPS
- TCRX N/A
- XBIT N/A
- Revenue
- TCRX $6,961,000.00
- XBIT N/A
- Revenue This Year
- TCRX $255.18
- XBIT N/A
- Revenue Next Year
- TCRX N/A
- XBIT N/A
- P/E Ratio
- TCRX N/A
- XBIT N/A
- Revenue Growth
- TCRX N/A
- XBIT N/A
- 52 Week Low
- TCRX $1.02
- XBIT $2.50
- 52 Week High
- TCRX $6.23
- XBIT $8.32
- Technical
- Relative Strength Index (RSI)
- TCRX 59.09
- XBIT 40.57
- Support Level
- TCRX $1.73
- XBIT $3.15
- Resistance Level
- TCRX $1.95
- XBIT $3.61
- Average True Range (ATR)
- TCRX 0.12
- XBIT 0.16
- MACD
- TCRX 0.01
- XBIT -0.05
- Stochastic Oscillator
- TCRX 84.85
- XBIT 8.00
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
About XBIT XBiotech Inc.
XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-inflammatory therapeutic antibodies as a treatment for cancer. Geographically, all of its operations are in the United States.